Deadline
Passed
Lead Plaintiff Deadline: July 06, 2021
Please Upload related files below
Fill in below.
Tell us the stocks you own using Snaptrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. Snaptrade only shares the tickers you own and your transaction history, not your account numbers. Using Snaptrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery- link your account with Snaptrade.
26
Nov 2019
03
May 2021
(1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx’s New Drug Application (“NDA”) for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.
In order to be included in the lawsuit, you must have incurred a loss on shares of ChemoCentryx purchased during the class period listed above.
If you suffered a loss in ChemoCentryx during the relevant time frame, you have until July 06, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.